MRNA trade ideas
Round Top Pattern. Greetings All,
Based on the rounding top pattern, I'm bearish on MRNA in the short-term. Target $116, which is also the 61.8% retracement level from the ATH ($189).
Happy Trading!
Disclaimer. My ideas are for informational purposes only. My ideas do not constitute solicitation, recommendation, endorsement, or offer to buy or sell any securities or other financial instruments. You should not construe any such information or other comments as legal, tax, investment, financial, or other advice. There are risks associated with investing in securities. Investing in stocks, bonds, exchange traded funds, mutual funds, options and money market funds involve risk of loss. Loss of principal is possible. Please exercise your own due diligence.
Moderna possible try to go longModerna stocks where sold by Astra Zeneca the last weeks. www.cnbc.com
MACD shows now for possible trend up. Let's give a try, maybe the down pressure after the selloff is over for Moderna Stock and we can target now new ATH.
HERCULES portfolio: now it’s better to consist of cashHERCULES’ mid-term trend chart is presented. Also the mid-term trend charts of the stocks that make up the portfolio are presented. ___
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
MRNA to 250 in MarMRNA could possibly reach as high as 250’s before or after the earnings report on 10 Mar.
Not only it may beat the earnings estimate, there are also quite positive news which may lead to explosive growth.
First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research
NEW YORK and LA JOLLA, CA—A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
…
The study sets the stage for additional clinical trials that will seek to refine and extend the approach—with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development.
…
The strategy of targeting naïve B cells with specific properties is called “germline-targeting,” as these young B cells display antibodies encoded by unmutated, or “germline” genes. Researchers believe the approach could also be applied to vaccines for other challenging pathogens such as influenza, dengue, Zika, hepatitis C viruses and malaria.
MRNA: the cup turns out to be a double top?MRNA’s mid-term trend chart is presented. ___
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
HERCULES: weekly portfolio course valuationHERCULES’ mid-term trend chart is presented. ___
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
MRNA - Watching for MondayJust watching this on Monday. Looks like a cup & handle, bottom of RSI, MACD about to reverse, gaining volume. May break through it's long time channel
MRNA: a misleading cup with a handle formation?MRNA’s short-, long and mid-term trend charts are presented. ___
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
$200 SoonPrevious high acting as support. Pattern is getting tight. Prime for a breakout to new highs. $200 psychological target.
Moderna to $227 before March 29Moderna new price target : $227
When: Before March 29
Growth: 28.25%
Buy : YES
Trade at your own risks
MRNA LongMRNA: Long Continuation based off weekly Fib Trend extentions. After a successful rejection the 146.46 level (golden ratio) bullish price action may continue to 212.28 with a break above exposing 229.75 followed by 255.04. Price in currently in consolidation as evidenced by the 4 hour time frame. Top side resistance will be tested as price remains in a upward channel since November 30 2020. Current support resides at the same level.
Cup and HandlePossible stop under handle low or MC/mid cup..or under 162.5 if you are being conservative (o:
C is too far away for stop, some use the last pivot low..
Can be volatile so if you do not like entry today, wait until tomorrow perhaps..
Not a recommendation
MRNA: a bigger cup with a handle pattern is formingMRNA’s short-, long- and mid-term trend charts are presented.
In both the weekly and daily charts the trend continues to be rising.____
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
The HERCULES portfolio The HERCULES portfolio is introduced.
The stocks that make up the portfolio were selected according to the following criteria:
1) belong to different business sectors
2) the sectors have great future growth prospects
3) their medium to long-term trend is upward
4) be growth shares
5) be financially healthy
6) either be profitable or have the prospect of becoming
7) their technical picture reveals that they will likely over perform the market.
Below are presented the mid-term trend charts of the stocks that make up the portfolio.
The HERCULES portfolio is designed so as to, although it is aggressive, let the investor to sleep calm at night.
In case of general market sharp correction the stocks of HERCULES portfolio have the potential to come back into their upward trend.
New stocks may be added to the portfolio in the coming period and some removed from it depending on their course.
Next follows the mid-term performance chart of HERCULES portfolio without the CRSR.
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
Clean Setup in MRNAIt hasn't broken out yet, but MRNA looks poised to continue higher. I wouldn't mind a starter here because risk is so easy to manage. This name seems like it will be obvious in hindsight, but people overlook it now because they want the hot new stock. This technology is revolutionary and will become brand name. It doesn't have the upside that it once had, but that doesn't mean you shouldn't want to own it.
MRNA, RSI Indicator left the overbought zone on Feb 11, 2021This is a signal that MRNA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked back and found 24 similar cases where MRNA's RSI Indicator left the overbought zone, and in 19 of them led to a successful outcome. Odds of Success: 79%. Current price $180.71 is above $74.10 the highest resistance line found by Tickeron A.I. Throughout the month of 01 /11/21 - 02/11/21, the price experienced a +56% Uptrend. During the week of 02/04/21 - 02/11/21, the stock enjoyed a +6% Uptrend growth.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Indicator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
MRNA broke above its upper Bollinger Band on January 29, 2021. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
MRNA long Fisher confirms again possible new highsLooking at side way consolidation to be over
here are the criterias on weekly chart
Fisher transform Positive
3&8 ema + on Weekly
3&8 ema + on 3 Days
8&34 ema + on weekly
Some basic E.W. to match
Weekly pivot respected
Wrong analysis if break 395 again in my books
